Asenapine-d3(Synonyms: Org 5222-d3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Asenapine-d3 (Synonyms: Org 5222-d3)

Asenapine-d3 (Org 5222-d3) 是 Asenapine 的氘代物。Asenapine (Org 5222) 属于非典型抗精神药物,是 5-羟色胺受体 (5-HT receptorspKi: 8.4-10.5)、肾上腺素受体 (adrenoceptorspKi: 8.9-9.5)、多巴胺受体 (dopamine receptorspKi: 8.9-9.4) 和组胺受体 (histamine receptorspKi: 8.2-9.0) 多种受体的拮抗剂。Asenapine 可用于精神分裂症和双相情感障碍的研究。

Asenapine-d3(Synonyms: Org 5222-d3)

Asenapine-d3 Chemical Structure

CAS No. : 1180843-72-4

规格 是否有货
1 mg Check price and availability
5 mg Check price and availability

* Please select Quantity before adding items.

生物活性

Asenapine-d3 (Org 5222-d3) is the deuterium labeled Asenapine. Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

288.79

Formula

C17H13D3ClNO

CAS 号

1180843-72-4

中文名称

阿塞那平 d3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73.

    [3]. Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务